Oxford BioMedica’s business update highlights that the manufacturing capacity expansion is progressing with all the work expected to be completed in early 2016. The development pipeline continues to progress with additional trials anticipated to commence in 2016. 2015 has been a year the group has undertaken a substantial capex programme in order to increase its manufacturing space in order to deliver on its contract with Novartis and other potential customers. 2016 looks set to be a busy year f ....
